Multivariable analysis of outcomes
| End point* . | RR or odds ratio (95%CI) . | P . |
|---|---|---|
| LFS #1† | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 1.09 (0.80-1.49) | .59 |
| MUD | 0.85 (0.61-1.20) | .36 |
| MMUD | 1.12 (0.73-1.73) | .60 |
| Leukemia relapse§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 3.67 (2.14-6.27) | < .01 |
| MUD | 3.05 (2.14-6.27) | < .01 |
| MMUD | 2.50 (1.23-5.07) | < .01 |
| NRM§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 0.31 (0.18-0.53) | < .01 |
| MUD | 0.61 (0.33-1.15) | < 13 |
| MMUD | 0.38 (0.24-0.59) | < .01 |
| Neutrophil recovery† | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 3.46 (2.69-4.44) | < .01 |
| MUD | 2.16 (1.69-2.75) | < .01 |
| MMUD | 2.17 (1.55-3.03) | < .01 |
| Platelet recovery§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 4.55 (3.46-5.99) | < .01 |
| MUD | 3.80 (2.77-5.22) | < .01 |
| MUDD | 3.23 (2.13-4.90) | < .01 |
| Grade II-IV acute GVHD§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 1.08 (0.82-1.43) | .57 |
| MUD | 1.83 (1.36-2.47) | < .01 |
| MMUD | 2.35 (1.52-3.63) | < .01 |
| Chronic GVHD§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 1.58 (1.03-2.43) | .03 |
| MUD | 1.71 (1.12-2.63) | .01 |
| MMUD | 2.07 (1.19-3.60) | .01 |
| End point* . | RR or odds ratio (95%CI) . | P . |
|---|---|---|
| LFS #1† | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 1.09 (0.80-1.49) | .59 |
| MUD | 0.85 (0.61-1.20) | .36 |
| MMUD | 1.12 (0.73-1.73) | .60 |
| Leukemia relapse§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 3.67 (2.14-6.27) | < .01 |
| MUD | 3.05 (2.14-6.27) | < .01 |
| MMUD | 2.50 (1.23-5.07) | < .01 |
| NRM§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 0.31 (0.18-0.53) | < .01 |
| MUD | 0.61 (0.33-1.15) | < 13 |
| MMUD | 0.38 (0.24-0.59) | < .01 |
| Neutrophil recovery† | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 3.46 (2.69-4.44) | < .01 |
| MUD | 2.16 (1.69-2.75) | < .01 |
| MMUD | 2.17 (1.55-3.03) | < .01 |
| Platelet recovery§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 4.55 (3.46-5.99) | < .01 |
| MUD | 3.80 (2.77-5.22) | < .01 |
| MUDD | 3.23 (2.13-4.90) | < .01 |
| Grade II-IV acute GVHD§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 1.08 (0.82-1.43) | .57 |
| MUD | 1.83 (1.36-2.47) | < .01 |
| MMUD | 2.35 (1.52-3.63) | < .01 |
| Chronic GVHD§ | ||
| Double UCB donor‡ | 1.0 | |
| MRD | 1.58 (1.03-2.43) | .03 |
| MUD | 1.71 (1.12-2.63) | .01 |
| MMUD | 2.07 (1.19-3.60) | .01 |
Other factors that were significant in multivariable analysis for LFS: High risk disease RR 2.44 (95%CI, 1.8-3.21), P < .01. Years from diagnosis to transplantation, 1 to 2 years RR 0.58 (95%CI, 0.42-0.81), P < .01, > 2 years RR 0.44 (95%CI, 0.31-0.61), P < .01. Significant for leukemia relapse: High risk disease RR 3.07 (95%CI, 2.12-4.43), P < .01. Age at transplantation (continuous/decade) RR 0.86 (95%CI, 0.76-0.96), P < .01. Years from diagnosis to transplantation, 1 to 2 years RR 0.57 (95%CI, 0.38-0.87), P < .01, > 2 years RR 0.30 (95%CI, 0.18-0.48), P < .01. MDS RR 0.07 (95%CI, 0.01-0.51), P < .01. Significant for NRM: Age at transplantation (continuous/decade) RR 1.30 (95%CI, 1.12-1.51), P < .01; AML RR 0.63 (95%CI, 0.42-0.96), P = .03; MDS RR 3.06 (95%CI, 1.53-6.15), P < .01. Significant for neutrophil recovery: Age at transplantation (continuous/decade) RR 1.08 (95%CI, 1.00-1.16), P = .04. Significant for platelet recovery: MDS RR 0.29 (95%CI, 0.14-0.60), P < .01.Significant for grade II-IV acute GVHD: Donor or recipient seropositive RR 0.73 (95%CI, 0.59-0.89), P < .01. Significant for chronic GVHD: Age at transplantation (continuous/decade) RR 1.16 (95%CI, 1.04-1.30), P < .01.
Cox regression.
Denotes reference group.
Proportional hazards model of Fine and Gray.